Bausch Health leaves Medicaid, 340B programs as drugmakers face changing calculus on pricing

Taking stock of the drug industry, from the lab to the medicine chest

October 28, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Bausch Health leaves Medicaid and 340B programs as drugmakers face changing calculus on pricing The shift comes as the industry is under pressure from the Trump administration to lower prices and is confronting other changes in the health care system. By Ed Silverman STAT+ | Eli Lilly, NVIDIA team up to build pharma's biggest AI supercomputer Eli Lilly to use NVIDIA chips in new supercomputer billed as the most powerful in the pharmaceutical industry. Will run 100% on renewable energy. By Brittany Trang Opinion: America needs a trusted national patient registry for leucovorin and autism Fast-tracking leucovorin for autism may help families sooner, but a national evidence registry is needed to track how the drug performs in real life. By Srinivas Sridhar Adobe STAT+ | Psychedelic-like therapy posts encouraging early data, as regulators clear at-home testing Delix Therapeutics' drug called zalsupindole is a neuroplastogen designed to provide the therapeutic benefits of classic psychedelics without the 'trip.' By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser